In a filing, Entero Therapeutics Inc revealed its Chief Financial Officer Romano Sarah unloaded Company’s shares for reported $465.0 on Jan 06 ’25. In the deal valued at $0.64 per share,727 shares were sold. As a result of this transaction, Romano Sarah now holds 17,287 shares worth roughly $10545.07.
Then, Romano Sarah sold 476 shares, generating $212 in total proceeds. Upon selling the shares at $0.45, the Chief Financial Officer now owns 18,014 shares.
Before that, Romano Sarah sold 621 shares. Entero Therapeutics Inc shares valued at $664 were divested by the Chief Financial Officer at a price of $1.07 per share. As a result of the transaction, Romano Sarah now holds 18,490 shares, worth roughly $11278.9.
Price Performance Review of ENTO
On Monday, Entero Therapeutics Inc [NASDAQ:ENTO] saw its stock jump 23.31% to $0.61. Over the last five days, the stock has gained 26.82%. Entero Therapeutics Inc shares have fallen nearly -1.93% since the year began. Nevertheless, the stocks have fallen -91.97% over the past one year. While a 52-week high of $9.35 was reached on 03/03/25, a 52-week low of $0.19 was recorded on 01/21/25. SMA at 50 days reached $0.5488, while 200 days put it at $0.8557.
Levels Of Support And Resistance For ENTO Stock
The 24-hour chart illustrates a support level at 0.4733, which if violated will result in even more drops to 0.3367. On the upside, there is a resistance level at 0.8233. A further resistance level may holdings at 1.0367. The Relative Strength Index (RSI) on the 14-day chart is 64.83, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0234, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 64.53%. Stochastics %K at 28.52% indicates the stock is a holding.
